Nomination Committee appointed for Qlife Holding's Annual General Meeting 2021
In accordance with the decision at Qlife Holding's Annual General Meeting 2020, the company's Chairman of the Board has convened a Nomination Committee to prepare proposals for the Company's Annual General Meeting 2021.
The Nomination Committee consists of the following persons, who together represent approximately 39 percent of the company's shares and votes.
- Sören Skjärbäk, appointed by PKV Consult IVS,
- Sören Amund Henriksen, appointed by KMD Ventures A/S,
- Christian Månsson, appointed by Jimmie Landerman, and
- Mette Gross, Chairman of the Board.
The Nomination Committee's proposal will be presented in the notice convening the Annual General Meeting 2021 and on the company's website, www.qlifeholding.com.
Shareholders who wish to submit proposals to the Nomination Committee are welcome to contact the Nomination Committee at the company's address, Hamntorget 3, 252 21 Helsingborg. In order for the Nomination Committee to be able to consider a proposal, the proposal must have been received in due time before the Annual General Meeting, and no later than 5th February 2021.
For further information please contact:
Mette Gross, Chairman Qlife Holding AB
E-mail: mette.gross@lehdab.com
Tel. No.: +46 (0)73-517 85 25
About Qlife
Qlife is a medical device company that seeks to revolutionize the clinical biomarker market for whole blood testing by taking it out of the lab and into the homes. This will facilitate easy access to blood sample results and in turn facilitate increased monitoring of parameters that enables care improvement.
Shares for Qlife are being traded on Nasdaq First North Growth Market in Stockholm with G&W Fondkommission as certified advisor (phone: +46 (0) 8-503 000 50, e-mail: ca@gwkapital.se).
Read more on Egoo.health, Qlifeholding.com or follow us on LinkedIn.